Literature DB >> 15725800

Prognostic value of lymphatic and blood vessel invasion in neuroendocrine tumors of the lung.

Katharina Schmid1, Peter Birner, Verena Gravenhorst, Adelheid End, Silvana Geleff.   

Abstract

Few data on the influence of vessel invasion on the progression of neuroendocrine lung tumors are available. Because of the lack of specific markers, previous studies could not reliably discriminate lymphatic and blood vessels. By immunostaining for podoplanin, specific for lymphatic endothelium, and CD34 antigen, we assessed lymphatic and blood vessel invasion in 120 tissue specimens of patients with neuroendocrine lung tumors. Lymphovascular invasion was correlated with clinicopathologic parameters, and its prognostic relevance was evaluated. Lymphatic vessels were identified exclusively at the tumor invasion front, whereas blood capillaries were also seen within tumors. Lymphatic vessel as well as lymphatic and blood vessel invasion was prevalent in patients with high-grade neuroendocrine tumors and advanced tumor stages, closely associated with lymph node metastases (P < 0.0001). In univariate analysis, these two invasion types correlated with decreased disease-free survival (both P < 0.0001), whereas blood vessel invasion alone did not. In multivariate analysis, only tumor grade and lymph node status remained statistically significant factors for prognosis (P = 0.016 and P < 0.0001). Our results suggest that evaluation of lymphatic vessel invasion is important in neuroendocrine lung tumors serving as a prognostic parameter for disease-free survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15725800     DOI: 10.1097/01.pas.0000149706.74216.b6

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

Review 1.  Lymphangiogenesis and lymphatic vessel remodelling in cancer.

Authors:  Steven A Stacker; Steven P Williams; Tara Karnezis; Ramin Shayan; Stephen B Fox; Marc G Achen
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

2.  Impact of lymphatic and/or blood vessel invasion in stage II gastric cancer.

Authors:  Chun-Yan Du; Jing-Gui Chen; Ye Zhou; Guang-Fa Zhao; Hong Fu; Xue-Ke Zhou; Ying-Qiang Shi
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

3.  Clinical epidemiology of gastric cancer in Hehuang valley of China: a 10-year epidemiological study of gastric cancer.

Authors:  Su Yan; Bin Li; Zhen-Zhong Bai; Jun-Qi Wu; Da-Wei Xie; Ying-Cai Ma; Xu-Xiang Ma; Jun-Hui Zhao; Xin-Jian Guo
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

4.  Differing Lymphatic Vessels Density in Salivary Adenoid Cystic Carcinoma and Pleomorphic Adenoma.

Authors:  Richard Salzman; I Stárek; L Kučerová; A Skálová
Journal:  Pathol Oncol Res       Date:  2016-11-11       Impact factor: 3.201

5.  Clinical usefulness of D2-40 in non-small cell lung cancer.

Authors:  Kyung Hoon Min; Seoung Ju Park; Kyung Sun Lee; Sung Ho Hwang; So Ri Kim; Hee Moon; Hyo Jin Han; Myoung Ja Chung; Yong Chul Lee
Journal:  Lung       Date:  2010-11-25       Impact factor: 2.584

6.  Lymphatic vascular density and lymphangiogenesis during tumour progression of carcinoma ex pleomorphic adenoma.

Authors:  A B Soares; L Ponchio; P B Juliano; V C de Araújo; A Altemani
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

7.  Neither expression of VEGF-C/D nor lymph vessel density supports lymphatic invasion as the mechanism responsible for local spread of recurrent salivary pleomorphic adenoma.

Authors:  R Salzman; I Stárek; L Kučerová; A Skálová; J Hoza
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

8.  Impact of capillary invasion on the prognosis of gastric adenocarcinoma patients: A retrospective cohort study.

Authors:  Lian Xue; Xiao-Long Chen; Pan-Pan Lin; Yuan-Wei Xu; Wei-Han Zhang; Kai Liu; Xin-Zu Chen; Kun Yang; Bo Zhang; Zhi-Xin Chen; Jia-Ping Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Oncotarget       Date:  2016-05-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.